Valsartan, Losartan and Irbesartan use in the USA, UK, copyright and Denmark after the nitrosamine recalls: a descriptive cohort study
Valsartan, Losartan and Irbesartan use in the USA, UK, copyright and Denmark after the nitrosamine recalls: a descriptive cohort study
Blog Article
Objectives To examine valsartan, losartan and irbesartan usage and switching patterns in the nacrack.com USA, UK, copyright and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled.Design Retrospective cohort study.Setting USA, Canadian administrative healthcare data, Danish National Prescription Registry and UK primary care electronic health records.Participants Patients aged 18 years and older between January 2014 and December 2020.
Intervention Valsartan, losartan and irbesartan.Main outcome Monthly percentages of individual ARB episodes, new users and switches to another ARB, ACE inhibitors (ACEI) or calcium channel blockers containing products.Results We identified 10.8, 3.
2, 1.8 and 1.2 million ARB users in the USA, UK, copyright and Denmark, respectively.Overall proportions of valsartan, losartan and irbesartan use were 18.
4%, 67.9% and 5.2% in the USA; 3.1%, 48.
3% and 10.2% in the UK, 16.3%, 11.4% and 18.
3% in copyright, 1%, 93.5% and 0.6% in Denmark.In July 2018, we observed an immediate steep decline in the proportion of valsartan use in the USA and copyright.
A similar trend was observed in Denmark; however, the decline was click here only minimal.We observed no change in trends of ARB use in the UK.Accompanying the valsartan decline was an increase in switching to other ARBs in the USA, copyright and Denmark.There was a small increase in switching to ACEI relative to the valsartan-to-other-ARBs switch.
We also observed increased switching from other affected ARBs, losartan and irbesartan, to other ARBs throughout 2019, in the USA and copyright, although the usage trends in the USA remained unchanged.Conclusion The first recall notice for valsartan resulted in substantial decline in usage due to increased switching to other ARBs.Subsequent notices for losartan and irbesartan were also associated with increased switching around the time of the recall, however, overall usage trends remained unchanged.